Ignota Labs Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 9

Employees

  • Latest Deal Type
  • Seed

  • Latest Deal Amount
  • $7.85M

  • Investors
  • 16

Ignota Labs General Information

Description

Developer of medical technology designed to optimize the drug discovery process, eliminating compounds harmful to the environment and minimizing waste. The company's platform uses artificial intelligence algorithms to predict toxic endpoints, earlier in the drug discovery process, enabling the pharmaceutical industry to be more sustainable by reducing environmental damage and improving drug safety.

Contact Information

Formerly Known As
AbsoluteAi
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Saint Johns Innovation Centre, Saint Johns Innovation Park
  • Cowley Road
  • Cambridge CB4 0WS
  • England, United Kingdom
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Biotechnology
Corporate Office
  • Saint Johns Innovation Centre, Saint Johns Innovation Park
  • Cowley Road
  • Cambridge CB4 0WS
  • England, United Kingdom

Ignota Labs Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ignota Labs Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Seed Round 27-Feb-2025 $7.85M Completed Generating Revenue
5. Grant 28-Jan-2025 Completed Generating Revenue
4. Accelerator/Incubator 01-May-2024 Completed Generating Revenue
3. Equity Crowdfunding 24-Oct-2023 Completed Generating Revenue
2. Accelerator/Incubator 01-Oct-2023 $65.2K $479K Completed Generating Revenue
1. Seed Round 13-Sep-2023 $414K $414K Completed Product Development
To view Ignota Labs’s complete valuation and funding history, request access »

Ignota Labs Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed-3 Preferred
Seed-2 Preferred
Seed-1 Preferred
Ordinary 102,362 $0.000001 $3.54 $3.54 1x $3.54 4.58%
Ordinary 303,521 $0.000001 $1.35 $1.35 1x $1.35 13.57%
To view Ignota Labs’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Ignota Labs Patents

Ignota Labs Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20250188084-A1 Compounds and methods for modulating cdk9 activity Pending 05-Nov-2020
US-11339168-B2 Crystalline forms of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as syk inhibitors Active 22-Feb-2019
US-20230098309-A1 Crystalline forms of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[l,2-a]pyrazin-8-amine as syk inhibitors Active 22-Feb-2019
US-12152037-B2 Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as a syk inhibitor Active 22-Feb-2019
US-20200291035-A1 Solid forms of a syk inhibitor Active 22-Feb-2019 C07D487/04
To view Ignota Labs’s complete patent history, request access »

Ignota Labs Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ignota Labs Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds
AIX Ventures Venture Capital Minority
ARTIS (San Francisco) Venture Capital Minority
Blue Wire Capital Venture Capital Minority
Fiddlehead Ventures Venture Capital Minority
Gaingels Venture Capital Minority
You’re viewing 5 of 16 investors. Get the full list »

Ignota Labs Investments (1)

Ignota Labs’s most recent deal was a Corporate Asset Purchase with Kronos Bio (Clinical Pipeline Assets). The deal was made on 06-Oct-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Kronos Bio (Clinical Pipeline Assets) 06-Oct-2025 Corporate Asset Purchase Buildings and Property
To view Ignota Labs’s complete investments history, request access »

Ignota Labs FAQs

  • When was Ignota Labs founded?

    Ignota Labs was founded in 2021.

  • Where is Ignota Labs headquartered?

    Ignota Labs is headquartered in Cambridge, United Kingdom.

  • What is the size of Ignota Labs?

    Ignota Labs has 9 total employees.

  • What industry is Ignota Labs in?

    Ignota Labs’s primary industry is Drug Discovery.

  • Is Ignota Labs a private or public company?

    Ignota Labs is a Private company.

  • What is the current valuation of Ignota Labs?

    The current valuation of Ignota Labs is .

  • What is Ignota Labs’s current revenue?

    The current revenue for Ignota Labs is .

  • How much funding has Ignota Labs raised over time?

    Ignota Labs has raised $8.68M.

  • Who are Ignota Labs’s investors?

    AIX Ventures, ARTIS (San Francisco), Blue Wire Capital, Fiddlehead Ventures, and Gaingels are 5 of 16 investors who have invested in Ignota Labs.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process